The cumulative effect of postpartum weight retention from each pregnancy in a woman’s life may contribute to her risk of ultimately developing cardiovascular (CV) disease and type 2 diabetes. However, there is limited direct evidence supporting this hypothesis. Thus, we sought to characterize the impact of postpartum weight retention on the trajectories of cardiometabolic risk factors over the first 5 years after pregnancy. Three-hundred-and-thirty women underwent cardiometabolic characterization in pregnancy and at 3-months, 1-yr, 3-yr, and 5-yrs postpartum. They were stratified into 3 groups based on the magnitude of weight change between pre-pregnancy and 5-yrs postpartum as follows: weight gain <0% (n=100), weight gain 0-6% (n=110), and weight gain >6% (n=120). CV risk factors did not differ between these groups at 1-yr postpartum but showed a stepwise worsening across the groups at 3- and 5-yrs (Fig). Specifically, adverse lipids, insulin resistance, and CRP progressively worsened from the weight gain <0% group to weight gain 0-6% to weight gain >6% (all p<0.05). On logistic regression analyses of prediabetes/diabetes at 5-years postpartum, weight gain >6% was shown to be significant (adjusted OR 3.40 [1.63 to 7.09]). In conclusion, postpartum weight retention predicts trajectories of enhanced CV risk and rising glycemia over the first 5-yrs after delivery.


C.K. Kramer: Research Support; Boehringer Ingelheim Inc. C. Ye: None. A. Hanley: None. P.W. Connelly: None. B. Zinman: Consultant; Abbott Diabetes, Eli Lilly and Company, Novo Nordisk A/S, Novo Nordisk Canada Inc., Boehringer Ingelheim Inc., Merck & Co., Inc. R. Retnakaran: Research Support; Boehringer Ingelheim/Mount Sinai Hospital, Novo Nordisk. Other Relationship; Sanofi, Eli Lilly and Company.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at